{ "ok": true, "cik": "863894", "ticker": "VERU", "name": "VERU INC.", "filings": [ { "form": "8-K", "filed": "2026-09-08", "items": [ "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/863894/000119312526384430/0001193125-26-384430-index.htm" }, { "form": "10-Q", "filed": "2026-08-10", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/863894/000143774926026664/0001437749-26-026664-index.htm" }, { "form": "8-K", "filed": "2026-08-10", "items": [ "2.02 Results of Operations and Financial Condition", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/863894/000119312526341187/0001193125-26-341187-index.htm" }, { "form": "8-K", "filed": "2026-07-02", "items": [ "1.01 Entry into a Material Definitive Agreement", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/863894/000119312526294507/0001193125-26-294507-index.htm" }, { "form": "8-K", "filed": "2026-06-04", "items": [ "8.01 Other Events" ], "url": "https://www.sec.gov/Archives/edgar/data/863894/000143774926019478/0001437749-26-019478-index.htm" }, { "form": "10-Q", "filed": "2026-05-13", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/863894/000143774926016557/0001437749-26-016557-index.htm" } ], "events12m": 10, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0000863894.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=863894" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets, no buy or sell views.", "edgar": "🫧 Edgar looked up VERU INC. ($VERU). Last filing: 8-K (8.01 Other Events), 2026-09-08. 10 event filings (8-K) in the past twelve months.", "auditor": { "changes": [], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2024-09-30", "revenue": 16886419, "revenueGrowth1y": 0.03617000178806373, "revenueGrowthPerYear": -0.2064903203260472, "yearsOfData": 5, "operatingMargin": -2.1419023180699237, "operatingMarginPrior": -5.754584137726808, "netMargin": -2.238569705039298, "operatingCashFlow": -21682333, "capitalSpending": 158322, "freeCashFlow": -21840655, "researchAndDevelopment": 12782167, "researchShareOfRevenue": 0.7569495344157929, "cash": 24916285, "longTermDebt": null, "longTermDebtChange": null, "revenueHistory": [ { "fiscalYearEnd": "2020-09-30", "revenue": 42592060 }, { "fiscalYearEnd": "2021-09-30", "revenue": 61259528 }, { "fiscalYearEnd": "2022-09-30", "revenue": 39354352 }, { "fiscalYearEnd": "2023-09-30", "revenue": 16296958 }, { "fiscalYearEnd": "2024-09-30", "revenue": 16886419 } ], "totalEquity": 32316712, "totalAssets": 60418772, "equityRatio": 0.534878663207521, "returnOnEquity": -1.1697175752285691, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": 0.21, "dividendYearsRising": 1, "dividendCut": false, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "range80": { "low": 10453327.329023903, "high": 18770125.022738386, "baseline": 14243530.90206282, "n": 749, "band": "b00" }, "ifPaceHeld": { "low": 10453327.329023903, "high": 18770125.022738386 } }, "edgarette": "🔖 Exposure: revenue $16.9M (FY2024). Experience: revenue up 3.6% on the year, down 20.6% a year over 4 years; operating margin -214.2%, up from -575.5%. Soundness: equity 53.5% of assets, return on equity -117.0%, dividend per share up 1 year running. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $10.5M and $18.8M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A range, not a forecast. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -214.2% against a -3.8% median; growth 3.6% against 13.7%.", "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "summary": "Veru (VERU) grew revenue 3.6% in FY2024 to $17 million, operating margin -214% against a -3.8% median for pharmaceutical preparations, equity 53.5% of assets, and dividend per share up 1 year running. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
VERU INC. against its own record and its peers
Operating marginPeer median -3.8%-214.2%Revenue, on the yearPeer median 13.7%3.6%Equity of assetsPeer median 40.3%53.5%Return on equityPeer median -1.1%-117.0%Gold tick: the median of 100–118 peers with $50M+ revenue in pharmaceutical preparations
", "chartHorizon": "
Handed back now, or kept to compound
Of each dollar of profitHanded back per share$0.21up 1 year runningRevenue growth it managed3.6%last year, for comparison

Gold is paid out to shareholders; navy is kept in the business. Retained profit times return on equity is the pace a company can fund from itself. Facts from the filings, not a recommendation.

", "backtest": { "tests": 12, "hits": 4, "rate": 0.3333333333333333, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "registry": { "logged": "2026-09-20T15:20:32.096Z", "hash": "ff86c441c928df88", "status": "open" }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Veru (VERU) grew revenue 3.6% in FY2024 to $17 million, operating margin -214% against a -3.8% median for pharmaceutical preparations, equity 53.5% of assets, and dividend per share up 1 year running. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2024-09-30", "revenue": 16886419, "totalDebt": null, "cash": 24916285 }, "experience": { "revenueGrowth1y": 0.03617000178806373, "revenueGrowthPerYear": -0.2064903203260472, "operatingMargin": -2.1419023180699237, "operatingMarginPrior": -5.754584137726808, "netMargin": -2.238569705039298, "freeCashFlow": -21840655 }, "soundness": { "equityRatio": 0.534878663207521, "returnOnEquity": -1.1697175752285691, "payoutRatio": null, "dividendPerShare": 0.21, "dividendYearsRising": 1, "dividendCut": false, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "credibility": { "auditedYears": 5, "weight": "reasonable", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": null }, "range": { "low": 10453327.329023903, "high": 18770125.022738386, "baseline": 14243530.90206282, "coverage": 0.8, "method": "v3", "basis": "next fiscal year revenue: baseline = revenue x (1 + mean of one-year and three-year pace); range = 10th to 90th percentile of how SEC company-years of the same size band actually turned out", "calibratedOn": { "companyYears": 749, "sizeBand": "b00" }, "kind": "a calibrated range, not a forecast; no view on the share price", "track": { "backtest": { "tests": 12, "hits": 4, "rate": 0.3333333333333333, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "registry": { "logged": "2026-09-20T15:20:32.096Z", "hash": "ff86c441c928df88", "status": "open" }, "scorecard": "https://www.pops4.com/boards/scorecard" } }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0000863894.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=863894" } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same if-the-pace-held arithmetic applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so." } }